The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Promising combination of ixazomib, lenalidomide & dex in high-risk smoldering myeloma
Mark Bustoros, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the Phase II trial (NCT02916771) assessing the PFS and response rate following the combination of ixazomib, lenalidomide and dexamethasone for the treatment of high-risk smoldering multiple myeloma (SMM). Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Busteros discusses the promising efficacy, tolerability and response rate of this combination, before revealing his future expectations for this treatment.
